ContextVision launches New Products and Upgrades at RSNA 2017

At this year’s Annual Meeting of RSNA, the Radiological Society of North America (starting today), ContextVision launches a new product for ultrasound and an upgrade of the latest product for x-ray.

The new group of products for ultrasound, VolarView™, serves the needs of handheld ultrasound which is increasingly being used in the fast-growing point of care (POC) market. VolarView allows for efficient implementation on smartphone- and tablet-based systems as well as specially designed ultrasound devices.

“We expect the use of hand-held devices to grow dramatically in the future. Implementing our image enhancement algorithms on these smaller devices allows us to serve new players on the ultrasound market as well as present customers expanding into the hand-held segment”, said Anita Tollstadius, CEO.

The upgrade of the X-ray product has been designed to address the specific requirements for orthopedic imaging and facilitates low dose exposures with highest image quality. Superior dynamics of the image enhancement x-ray product allows system manufacturers to meet a broader variety of customer preferences.

For further information, please contact ContextVision’s CEO, Anita Tollstadius, at Mob: +46 70 337 30 26.

About ContextVision
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV.
For more information, please visit